Last reviewed · How we verify
Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial
Adjunctive Therapy of AndrographolidSulfonate in Community Acquired Pneumonia: A Multicenter, Randomized,Double-blinded, Placebo Controlled Clinical Trial. The hypothesis is that combination therapy with Andrographolid Sulfonatein injection and antibacterial is significantly better than antibacterial alone in achieving clinical stability among hospitalized CAP patients.
Details
| Lead sponsor | Qingfeng Pharmaceutical Group |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 462 |
| Start date | 2016-07 |
| Completion | 2019-06-30 |
Conditions
- Community Acquired Pneumonia
Interventions
- Andrographolid Sulfonate Injection (AS Injection)
- Cephalosporin
- Azithromycin, Minocycline or Doxycycline
- Amoxicillin-clavulantic acid
- Fluoroquinolones
- Placebo
Primary outcomes
- time to clinical stability — 14 days
- number of study participants with treatment-related adverse events as assessed by CTCAE v4.0 — 14 days
symptoms and signs, blood and urine routine, liver and kidney function monitoring, ECG, side effects of long-time using of antibiotics
Countries
China